Literature DB >> 30203592

Designing cancer immunotherapy trials with random treatment time-lag effect.

Zhenzhen Xu1, Yongsoek Park2, Boguang Zhen1, Bin Zhu3.   

Abstract

In some clinical settings such as the cancer immunotherapy trials, a treatment time-lag effect may be present and the lag duration possibly vary from subject to subject. An efficient study design and analysis procedure should not only take into account the time-lag effect but also consider the individual heterogeneity in the lag duration. In this paper, we present a Generalized Piecewise Weighted Logrank (GPW-Logrank) test, designed to account for the random time-lag effect while maximizing the study power with respect to the weights. Based on the proposed test, both analytic and numeric approaches are developed for the sample size and power calculation. Asymptotic properties are derived and finite sample efficiency is evaluated in simulations. Compared with the standard practice ignoring the delayed effect, the proposed design and analysis procedures are substantially more efficient when a random lag is expected; further, compared with the existing methods by Xu et al considering the fixed time-lag effect, the proposed approaches are significantly more robust when the lag model is misspecified. An R package (DelayedEffect.Design) is developed for implementation. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  cancer immunotherapy; clinical trial; nonproportional hazards assumption; random time-lag effect; sample size and power calculation; treatment time-lag effect

Mesh:

Year:  2018        PMID: 30203592      PMCID: PMC6279582          DOI: 10.1002/sim.7937

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Antibody therapeutics in cancer.

Authors:  Mark X Sliwkowski; Ira Mellman
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

3.  Sample size calculation for complex clinical trials with survival endpoints.

Authors:  J H Shih
Journal:  Control Clin Trials       Date:  1995-12

4.  Sample sizes based on the log-rank statistic in complex clinical trials.

Authors:  E Lakatos
Journal:  Biometrics       Date:  1988-03       Impact factor: 2.571

Review 5.  A clinical development paradigm for cancer vaccines and related biologics.

Authors:  Axel Hoos; Giorgio Parmiani; Kristen Hege; Mario Sznol; Hans Loibner; Alexander Eggermont; Walter Urba; Brent Blumenstein; Natalie Sacks; Ulrich Keilholz; Geoffrey Nichol
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

6.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

7.  Designing therapeutic cancer vaccine trials with delayed treatment effect.

Authors:  Zhenzhen Xu; Boguang Zhen; Yongsoek Park; Bin Zhu
Journal:  Stat Med       Date:  2016-11-02       Impact factor: 2.373

8.  Power and sample size calculation for log-rank test with a time lag in treatment effect.

Authors:  Daowen Zhang; Hui Quan
Journal:  Stat Med       Date:  2009-02-28       Impact factor: 2.373

9.  Statistical design of the Women's Health Trial.

Authors:  S Self; R Prentice; D Iverson; M Henderson; D Thompson; D Byar; W Insull; S L Gorbach; C Clifford; S Goldman
Journal:  Control Clin Trials       Date:  1988-06

10.  A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects.

Authors:  Pei He; Zheng Su
Journal:  Contemp Clin Trials Commun       Date:  2015-11-10
View more
  5 in total

1.  Cancer immunotherapy trial design with random delayed treatment effect and cure rate.

Authors:  Jianrong Wu; Jing Wei
Journal:  Stat Med       Date:  2021-11-15       Impact factor: 2.497

2.  Cancer immunotherapy trial design with delayed treatment effect.

Authors:  Jianrong Wu; Jing Wei
Journal:  Pharm Stat       Date:  2019-11-15       Impact factor: 1.234

3.  Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

Authors:  Zhenzhen Xu; Bin Zhu; Yongsoek Park
Journal:  Stat Med       Date:  2020-09-17       Impact factor: 2.497

4.  Examining evidence of time-dependent treatment effects: an illustration using regression methods.

Authors:  Kim M Jachno; Stephane Heritier; Robyn L Woods; Suzanne Mahady; Andrew Chan; Andrew Tonkin; Anne Murray; John J McNeil; Rory Wolfe
Journal:  Trials       Date:  2022-10-06       Impact factor: 2.728

5.  Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.

Authors:  Zhenzhen Xu; Yongsoek Park; Ke Liu; Bin Zhu
Journal:  J Hematol Oncol       Date:  2020-03-14       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.